Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: Expert consensus statement Journal Article

   

Authors:	Karanicolas, P. J.; Metrakos, P.; Chan, K.; Asmis, T.; Chen, E.; Kingham, T. P.; Kemeny, N.; Porter, G.; Fields, R. C.; Pingpank, J.; Dixon, E.; Wei, A.; Cleary, S.; Zogopoulos, G.; Dey, C.; D'Angelica, M.; Fong, Y.; Dowden, S.; Ko, Y. J.
Article Title:	Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: Expert consensus statement
Abstract:	Despite significant improvements in systemic therapy for patients with colorectal liver metastases (crlms), response rates in the first-line setting are not optimal, and response rates in the second-line setting remain disappointing. Hepatic arterial infusion pump (haip) chemotherapy has been extensively studied in patients with crlms, but it remains infrequently used. We convened an expert panel to discuss the role of haip in the contemporary management of patients with crlm. Using a consensus process, we developed these statements: • haip chemotherapy should be given in combination with systemic chemotherapy. • haip chemotherapy should be offered in the context of a multidisciplinary program that includes expertise in hepatobiliary surgery, medical oncology, interventional radiology, nursing, and nuclear medicine. • haip chemotherapy in combination with systemic therapy should be considered in patients with unresectable crlms who have progressed on first-line systemic treatment. In addition, haip chemotherapy is acceptable as first-line treatment in patients with unresectable colorectal liver metastases. • haip chemotherapy is not recommended in the setting of extrahepatic disease outside the context of a clinical trial. • haip chemotherapy in combination with systemic therapy is an option for select patients with resected colorectal liver metastases. These consensus statements provide a framework that clinicians who treat patients with crlm can use when considering treatment with haip. © 2014 Multimed Inc.
Keywords:	treatment outcome; treatment response; overall survival; cancer recurrence; fluorouracil; cancer growth; treatment duration; follow up; progression free survival; practice guideline; risk assessment; irinotecan; cancer specific survival; folinic acid; adjuvant chemotherapy; liver resection; oxaliplatin; floxuridine; artery thrombosis; liver metastases; randomized controlled trial (topic); meta analysis (topic); phase 3 clinical trial (topic); liver perfusion; phase 1 clinical trial (topic); colorectal metastases; medical procedures; intraarterial chemotherapy; systematic review (topic); colorectal liver metastasis; human; article; hepatic arterial infusion pump chemotherapy; unresectable metastases
Journal Title:	Current Oncology
Volume:	21
Issue:	1
ISSN:	1198-0052
Publisher:	Multimed Inc
Date Published:	2014-02-01
Start Page:	e129
End Page:	e136
Language:	English
DOI:	10.3747/co.21.1577
PROVIDER:	scopus
PMCID:	PMC3921037
PUBMED:	24523610
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84894350847&partnerID=40&md5=cb31f8acd4d2434dc6cccde33d251a05
Notes:	Export Date: 2 April 2014 -- CODEN: CUONF -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/49606